BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Liver
,
Anticancer prodrugs
,
Trichostatin A
,
rs2300478
,
BRCA1
,
Obesity
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Beta), P
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
CD29 Enriches for Cytotoxic Human CD4+ T Cells.
Ropivacaine inhibits the proliferation and migration of colorectal cancer cells through ITGB1.
Transcriptomics of CD29+/CD44+ cells isolated from hPSC retinal organoids reveals a single cell popu…
TMEM182 interacts with integrin beta 1 and regulates myoblast differentiation and muscle regeneratio…
ALKBH5 activates FAK signaling through m6A demethylation in ITGB1 mRNA and enhances tumor-associated…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
The Effect of Beta-blockers in Substance P Levels and the Swallowing Function
Differentiating the Effects of Substance P and Beta-endorphin
Substance P Challenge in Healthy Participants
Intravenous Beta-blockade for Improvement of Autonomic Activity
TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ